REGN
REGENERON PHARMACEUTICALS, INC.Evidence as of 2026-09-03Overview · REGENERON PHARMACEUTICALS, INC.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent inject…
Management team
- Mr. Joseph J. LaRosa · Executive VP, General Counsel & SecretaryFind on LinkedIn
- Mr. Ryan Crowe · Senior Vice President of Investor Relations & Strategic AnalysisFind on LinkedIn
- Mr. Christopher R. Fenimore CPA · Senior VP of Finance & CFOFind on LinkedIn
- Mr. Bob McCowan · Senior VP of IT & Chief Information OfficerFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
+0.3 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
The evidence balance is Mixed (+0.3 of a possible +2; it was +0.3 before the debate) with high confidence. Revenue rose from $ 3,605,400,000 in fiscal Q1 2026 (fiscal quarter ended 2026-03-31) to $ 4,290,700,000 in fiscal Q2 2026 (fiscal quarter ended 2026-06-30). Operating income expanded from $ 642,900,000 to $ 1,293,500,000 over the same quarters, implying operating margin moved from about 17.8% to about 30.2%.
Net income increased from $ 727,200,000 in fiscal Q1 2026 to $ 1,296,900,000 in fiscal Q2 2026, and diluted EPS rose from $ 6.75 to $ 12.23. Weighted‑average diluted shares outstanding declined from 107,700,000 to 106,000,000 shares, a reduction of 1,700,000 shares quarter‑to‑quarter. Trailing twelve‑month free cash flow is $ 4,232,100,000 (or $ 39.9255 per diluted share), the market price of $ 852.03 implies a price/FCF of 21.34 (FCF yield ~ 4.69%), trailing EPS is $ 45.41 with a trailing P/E of 18.76, and enterprise value of $ 79,583,372,373 implies an EV/EBITDA of 17.66.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Revenue increased from 3,605,400,000 USD in fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo) to 4,290,700,000 USD in fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo).
XBRL companyfacts · 0000872589-26-000016Operating income expanded from 642,900,000 USD in fiscal Q1 2026 (2026-01-01 to 2026-03-31, 3mo) to 1,293,500,000 USD in fiscal Q2 2026 (2026-04-01 to 2026-06-30, 3mo), implying operating margin rose from about 17.8% (642,900,000 / 3,605,400,000) to about 30.2% (1,293,500,000 / 4,290,700,000).
XBRL companyfacts · 0000872589-26-000025Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
A Form 4 filing for REGENERON PHARMACEUTICALS, INC. was submitted on 2026-08-21 (the 4 filed 21 August 2026).
4 filed 2026-08-21A Form 4 filing for REGENERON PHARMACEUTICALS, INC. was submitted on 2026-08-20 (the 4 filed 20 August 2026).
4 filed 2026-08-20Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
Momentum measures show price strength: 3-month momentum is +37.7% and 12-1 momentum is +36.8%, with rank_momentum_12_1 at the 73th percentile of the 547-stock research universe on 2026-09-02.
Moneyta signal set · 2026-09-02weakened in debateThe 3-year maximum drawdown is -59.7% and the current drawdown from the 3-year high is -28.5%, with rank_drawdown_3y at the 32th percentile of the 547-stock research universe on 2026-09-02.
Moneyta signal set · 2026-09-02Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
As of 2026-09-02T13:45:47.228469+00:00, REGN is held in the IVV ETF at a weight of 0.1% of that fund.
ETF constituents · market dataA Form 4 filing for REGN with the 4 filed 20 August 2026 was filed on 2026-08-20 (parse_status: skipped, primary_doc_url: null).
Form 4 × 2 (90d window not enforced here)Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
A class-action investor notice for Regeneron lists a lead plaintiff deadline of September 14, 2026 and alleges investor losses after the stock plunged due to allegedly misleading financial statements; the notice was published 2 September 2026.
News · globenewswire.com · 2026-09-02A law firm press release on 2 September 2026 urges Regeneron investors to act in a newly filed class action alleging investor harm related to the company.
News · globenewswire.com · 2026-09-02Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
On 2026-08-19, Joseph J. LaRosa (EVP General Counsel and Secretary) reported an acquisition (action "code M") of 12,282 shares for a reported aggregate value of "$4.7M", implying about "$382.56 per share"; the filing does not indicate a trading plan.
Form 4 · LAROSA JOSEPH J (EVP General Counsel and Secret) · $4.7M code M · 2026-08-19On 2026-08-19, Joseph J. LaRosa (EVP General Counsel and Secretary) reported a disposition (action "code F") of 9,019 shares for a reported aggregate value of "$7.5M", implying about "$831.74 per share"; the filing does not indicate a trading plan.
Form 4 · LAROSA JOSEPH J (EVP General Counsel and Secret) · $4.7M code M · 2026-08-19Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
Under the stated discount and terminal assumptions, today's price implies a perpetual free cash flow (FCF) growth rate of 10.58% (implied_growth = 0.1058).
Valuation inputs · SEC XBRL + stored EOD closeTrailing twelve‑month free cash flow was $4,232,100,000 (fcf_ttm = 4232100000.0), which equals $39.9255 of FCF per diluted share (fcf_per_share = 39.9255 based on shares_diluted_wavg = 106000000.0).
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
The featured fundamentals show quarter-to-quarter operational improvement: revenue, operating income, net income, and diluted EPS all rose materially from Q1 to Q2 2026, with operating margin expanding from ~17.8% to ~30.2% and a modest reduction in diluted shares outstanding. Momentum metrics (3-month +37.7%) and low market-sensitivity (beta 0.49, correlation 0.18) align with an improving stock-specific technical picture rather than a purely market-driven move. Trailing FCF per share ($39.93) and a mid-teens trailing P/E (18.8) provide context that underlying cash generation is substantial, even though some valuation multiples (price/FCF ~21.3; EV/EBITDA ~17.7) are not ultra-cheap. The bear case leans on a large 3-year drawdown and active litigation headlines, but those points are broader, partly backward-looking, and coexist with recent strong operating results and insider activity showing both acquisitions and dispositions. Financial advisors often suggest weighing recent operational improvement and cash-flow metrics alongside headline risks; here the strongest evidence for a favorable read is the demonstrable quarterly earnings and margin expansion supported by cash-flow per share data.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.30
29 surviving claims rest on 15 distinct sources; the heaviest analyst carries 17% of them, and 97% of what the desk raised survived the debate.
The surviving set is moderately robust but not ironclad: 29 claims draw on 15 sources, so a handful of documents carry outsized weight. Because one analyst contributed a sizable share and nearly all desk points survived debate, these reads are durable but sensitive to a small number of source corrections or new filings.
Peer context · computed, not argued
12-1 momentum ranks 3rd of 4 in Biotechnology (as of 2026-09-02).
90-day volatility ranks 3rd of 4 in Biotechnology (as of 2026-09-02).
dividend yield ranks 1st of 4 in Biotechnology (as of 2026-09-02).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
10 filings· 2 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+1.7 to the score
2 documents
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes+0.0 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash−0.3 to the score
2 holdings records
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.0 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
2 filings· 1 cited
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state — stated and inferred flags kept apart.
Read by Talbot+0.0 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on REGN Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.